BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35476700)

  • 1. Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma.
    Peng S; Chen S; Hu W; Mei J; Zeng X; Su T; Wang W; Chen Z; Xiao H; Zhou Q; Li B; Xie Y; Hu H; He M; Han Y; Tang L; Ma Y; Li X; Zhou X; Dai Z; Liu Z; Tan J; Xu L; Li S; Shen S; Li D; Lai J; Peng B; Peng Z; Kuang M
    Cancer Immunol Res; 2022 Jun; 10(6):728-744. PubMed ID: 35476700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
    Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
    Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
    Lin Z; Jiang C; Wang P; Chen Q; Wang B; Fu X; Liang Y; Zhang D; Zeng Y; Liu X
    Theranostics; 2023; 13(12):4166-4181. PubMed ID: 37554274
    [No Abstract]   [Full Text] [Related]  

  • 4. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
    Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy.
    Shou J; Mo F; Zhang S; Lu L; Han N; Liu L; Qiu M; Li H; Han W; Ma D; Guo X; Guo Q; Huang Q; Zhang X; Ye S; Pan H; Chen S; Fang Y
    Front Immunol; 2022; 13():1000681. PubMed ID: 36248865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
    Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
    Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and perspectives of immune-based therapies for hepatocellular carcinoma.
    Aerts M; Benteyn D; Van Vlierberghe H; Thielemans K; Reynaert H
    World J Gastroenterol; 2016 Jan; 22(1):253-61. PubMed ID: 26755874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma.
    Shimizu K; Kotera Y; Aruga A; Takeshita N; Katagiri S; Ariizumi S; Takahashi Y; Yoshitoshi K; Takasaki K; Yamamoto M
    Hum Vaccin Immunother; 2014; 10(4):970-6. PubMed ID: 24419174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
    Lu F; Ma XJ; Jin WL; Luo Y; Li X
    Front Immunol; 2021; 12():690565. PubMed ID: 34054880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma.
    Li X; Zhang Z; Lin G; Gao Y; Yan Z; Yin H; Sun B; Wang F; Zhang H; Chen H; Cao D
    Tumour Biol; 2016 Aug; 37(8):11267-78. PubMed ID: 26951511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.
    Lee JH; Lee Y; Lee M; Heo MK; Song JS; Kim KH; Lee H; Yi NJ; Lee KW; Suh KS; Bae YS; Kim YJ
    Br J Cancer; 2015 Dec; 113(12):1666-76. PubMed ID: 26657650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
    Awad MM; Govindan R; Balogh KN; Spigel DR; Garon EB; Bushway ME; Poran A; Sheen JH; Kohler V; Esaulova E; Srouji J; Ramesh S; Vyasamneni R; Karki B; Sciuto TE; Sethi H; Dong JZ; Moles MA; Manson K; Rooney MS; Khondker ZS; DeMario M; Gaynor RB; Srinivasan L
    Cancer Cell; 2022 Sep; 40(9):1010-1026.e11. PubMed ID: 36027916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy.
    Han Y; Wu Y; Yang C; Huang J; Guo Y; Liu L; Chen P; Wu D; Liu J; Li J; Zhou X; Hou J
    J Transl Med; 2017 Mar; 15(1):64. PubMed ID: 28330473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer.
    Zhang X; Xu Z; Dai X; Zhang X; Wang X
    Front Immunol; 2023; 14():1104860. PubMed ID: 36761724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
    Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.